BioWorld

Sep. 30, 2005

Cypress' Stock Plunges After Phase III Miss In Fibromyalgia

Cypress Bioscience Inc. lost more than half its value Thursday after announcing that a pivotal Phase III study of milnacipran missed its primary endpoint as a treatment for pain associated with fibromyalgia. (BioWorld Today) Read More

Sirna's RNAi Work Lands $250M Deal With Allergan

New Research: Target Host Cells To Help Fight Viruses

Avalon Sets IPO Price: $28.9M Pipeline Boost

Genomic Health's IPO Adds $60M For Breast Cancer Test

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...